This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPhase Holographic Imaging PHI（PHI）株式概要A medical technology company, develops and markets non-invasive time-lapse imaging instruments in Sweden and internationally. 詳細PHI ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6報酬過去5年間の収益は年間0.8%増加しました。 リスク分析キャッシュランウェイが1年未満である 株式の流動性は非常に低い 収益が 100 万ドル未満 ( SEK11M )意味のある時価総額がありません ( SEK169M )+1 さらなるリスクすべてのリスクチェックを見るPHI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 6.46466.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-26m30m2016201920222025202620282031Revenue SEK 29.6mEarnings SEK 3.8mAdvancedSet Fair ValueView all narrativesPhase Holographic Imaging PHI AB (publ) 競合他社Nosa PlugsSymbol: OM:NOSAMarket cap: SEK 134.8mBrainCoolSymbol: OM:BRAINMarket cap: SEK 312.0mSciBase HoldingSymbol: OM:SCIBMarket cap: SEK 332.3mRedsense MedicalSymbol: NGM:REDSMarket cap: SEK 93.7m価格と性能株価の高値、安値、推移の概要Phase Holographic Imaging PHI過去の株価現在の株価SEK 6.4652週高値SEK 9.0052週安値SEK 4.23ベータ1.051ヶ月の変化0%3ヶ月変化-4.44%1年変化31.84%3年間の変化-73.74%5年間の変化-75.25%IPOからの変化-56.93%最新ニュースお知らせ • Jan 01Phase Holographic Imaging Announces Resignation of Mats Lundwall as Director, Effective December 30, 2025Phase Holographic Imaging announced that Mats Lundwall, at his own request, has resigned from his position on the company's Board of Directors, effective December 30, 2025.お知らせ • Sep 26Phase Holographic Imaging PHI AB (publ) to Report First Half, 2026 Results on Dec 19, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2026 results on Dec 19, 2025お知らせ • Aug 28Phase Holographic Imaging PHI AB (publ) to Report Q1, 2026 Results on Sep 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2026 results on Sep 26, 2025お知らせ • Jun 26Phase Holographic Imaging Phi AB (Publ) Announces Executive and Board Appointments, Effective from 1 July 2025Phase Holographic Imaging PHI AB (publ) announced appointment of Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for company's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities. Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025.お知らせ • May 28Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2025 Results on Jun 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2025 results on Jun 26, 2025お知らせ • May 23Phase Holographic Imaging Phi AB (publ) Revises Revenue Guidance for Fiscal Year Ended on April 30, 2025Phase Holographic Imaging PHI AB (publ) revised revenue guidance for Fiscal Year ended on April 30, 2025. For the period, the company expects total sales to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.最新情報をもっと見るRecent updatesお知らせ • Jan 01Phase Holographic Imaging Announces Resignation of Mats Lundwall as Director, Effective December 30, 2025Phase Holographic Imaging announced that Mats Lundwall, at his own request, has resigned from his position on the company's Board of Directors, effective December 30, 2025.お知らせ • Sep 26Phase Holographic Imaging PHI AB (publ) to Report First Half, 2026 Results on Dec 19, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2026 results on Dec 19, 2025お知らせ • Aug 28Phase Holographic Imaging PHI AB (publ) to Report Q1, 2026 Results on Sep 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2026 results on Sep 26, 2025お知らせ • Jun 26Phase Holographic Imaging Phi AB (Publ) Announces Executive and Board Appointments, Effective from 1 July 2025Phase Holographic Imaging PHI AB (publ) announced appointment of Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for company's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities. Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025.お知らせ • May 28Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2025 Results on Jun 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2025 results on Jun 26, 2025お知らせ • May 23Phase Holographic Imaging Phi AB (publ) Revises Revenue Guidance for Fiscal Year Ended on April 30, 2025Phase Holographic Imaging PHI AB (publ) revised revenue guidance for Fiscal Year ended on April 30, 2025. For the period, the company expects total sales to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.お知らせ • Mar 12Phase Holographic Imaging Announces Next Generation HoloMonitorPhase Holographic Imaging (PHI) announced that the next generation of PHI's live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internationally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine. The HoloMonitor CellSync marks the first in a series of models, with the long-term goal of delivering a clinical-grade product designed to set a new standard for automated quality control in cell and gene therapy manufacturing. The series is expected to include the latest developments in image processing and artificial intelligence. Manufactured by production partner in accordance with ISO 9001 standards, the HoloMonitor CellSync builds on the success of its predecessor, offering non-invasive, real-time imaging of live cells. It incorporates the latest advancements in PHI's core imaging technology, including an updated camera module and enhanced automated cell segmentation, which has been developed over the past two years.お知らせ • Feb 11Phase Holographic Imaging Announces CEO ChangesRecent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company's clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead. Anders will step down immediately and assist with the transition. Ivan Jurkovic, PHI board member and Altium group CFO, will serve as the acting CEO of PHI during the recruitment process. In his current technology developer role, PHI's founding board member and former CEO, Peter Egelberg, will assist in product development and technical matters. Ivan Jurkovic (Board member, born 1984) is an experienced financial executive with experience in the pharmaceutical industry, beverage industry and IT industry. Mr. Jurkovic currently holds the position of Chief Financial Officer at Altium SA. As part of his role at Altium, Mr. Jurkovic is responsible for Altium's financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth.お知らせ • Nov 20Phase Holographic Imaging PHI AB (publ) to Report First Half, 2025 Results on Dec 19, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2025 results on Dec 19, 2024お知らせ • Nov 14Phase Holographic Imaging PHI AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 64.312816 million.Phase Holographic Imaging PHI AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 64.312816 million. Security Name: Shares Security Type: Common Stock Securities Offered: 35,729,342 Price\Range: SEK 1.8 Transaction Features: Rights Offeringお知らせ • Oct 17Phase Holographic Imaging Announces CEO Changes, Effective November 1, 2024The board of Phase Holographic Imaging (PHI) has appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson. Starting November 1, 2024, Anders Månsson will succeed Patrik Eschricht as CEO of PHI. Månsson brings over 25 years of experience in the international Health & Life Sciences field, having held senior-level positions in both large multinationals and smaller biotech companies. Most recently, he served as CEO of Oncoinvent ASA, and he has also held numerous leadership roles, including CEO, Chairman, and Board Member positions. He is currently a board member of EQL Pharma AB and a Partner and Board Member at Immetric AB. Månsson's previous roles also include CEO of LIDDS AB, the biopharmaceutical company RhoVac AB, and stem cell research-based company Amniotics AB. He studied for an Executive MBA at Business School Lausanne, Switzerland. As CEO of PHI, Anders will be responsible for driving the company's future development, with a particular focus on R&D, product development, and establishing PHI as a leader in non-invasive cell quality control technologies.お知らせ • Jul 24Phase Holographic Imaging PHI AB (publ) to Report Q3, 2025 Results on Aug 19, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2025 results on Aug 19, 2024お知らせ • Jul 22Phase Holographic Imaging PHI AB (publ) Announces Resignation of Leland Foster as Board MemberPhase Holographic Imaging PHI AB (publ) announced resignation of Leland Foster as board member. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments effective from July 22, 2024. Leland Foster, elected board member in 2012, has been a pivotal figure on PHI's board, providing invaluable guidance and insight drawn from his extensive experience in the industry. His contributions have been instrumental in steering the company towards innovation and growth.お知らせ • Jun 27Phase Holographic Imaging PHI AB (publ) to Report Q1, 2025 Results on Sep 16, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2025 results on Sep 16, 2024お知らせ • Mar 27Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2024 Results on Jun 26, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2024 results on Jun 26, 2024お知らせ • Mar 14Phase Holographic Imaging PHI AB (Publ) Appoints Ivan Jurkovic as Ordinary Board MemberPhase Holographic Imaging PHI AB (publ) held an extraordinary general meeting. The extraordinary general meeting resolved that the board of directors shall consist of six (6) ordinary board members, without deputy board members. For the period until the next annual general meeting, the general meeting resolved to elect Ivan Jurkovic as ordinary board member. Ivan Jurkovic, born in 1984, is an experienced financial business executive with experience from the pharmaceutical, beverage and IT industries. Jurkovic currently holds the position of Chief Financial Officer of Altium S.A. Within the scope of his assignment at Altium S.A., Jurkovic is responsible for the financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth.お知らせ • Jan 31Phase Holographic Imaging PHI AB (publ) to Report Q3, 2024 Results on Mar 27, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2024 results on Mar 27, 2024Reported Earnings • Dec 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr1.23m (down 55% from 2Q 2023). Net loss: kr5.38m (loss widened 1.3% from 2Q 2023).分析記事 • Nov 07Phase Holographic Imaging PHI (NGM:PHI) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Sep 21Phase Holographic Imaging PHI AB (publ) to Report First Half, 2024 Results on Dec 21, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2024 results on Dec 21, 2023Reported Earnings • Sep 20First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr2.73m (up 34% from 1Q 2023). Net loss: kr4.30m (loss narrowed 25% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.お知らせ • Sep 17Phase Holographic Imaging PHI AB (publ) to Report Q1, 2024 Results on Sep 20, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2024 results on Sep 20, 2023分析記事 • Jul 25Phase Holographic Imaging PHI (NGM:PHI) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Jul 04European Patent Office Intends to Grant Phase Holographic Imaging AB Patent on Synthetic AntibodiesPhase Holographic Imaging AB (PHI) announces that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies. The patent application "EP329447 Molecularly Imprinted Polymers" was submitted by PHI together with Germany's federal institute for materials research (BAM). PHI's corresponding patents concerning synthetic antibodies in the US and Japan were granted in 2020 and 2022, respectively. In spring 2023, PHI established the subsidiary PHI MIPS AB to house the synthetic antibody patent family and facilitate its business potential for the GlycoImaging project's outcome.お知らせ • Jun 27Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 12, 2023Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 12, 2023.Reported Earnings • Jun 27Full year 2023 earnings released: kr1.13 loss per share (vs kr1.76 loss in FY 2022)Full year 2023 results: kr1.13 loss per share (improved from kr1.76 loss in FY 2022). Revenue: kr9.90m (up 21% from FY 2022). Net loss: kr23.2m (loss narrowed 8.7% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.お知らせ • May 25Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2023 Results on Jun 23, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2023 results on Jun 23, 2023お知らせ • May 10Phase Holographic Imaging Phi AB (Publ) Elects Goran Dubravcic Elected as A New Member of the BoardPhase Holographic Imaging Phi AB (Publ) announced that Goran Dubravcic elected as a new member of the Board. The newly elected board member Goran Dubravcic is the CEO of Altium SA, which currently owns 11.8% of the shares in the Company.Recent Insider Transactions Derivative • May 08Director exercised options to buy kr105k worth of stock.On the 2nd of May, Leland Foster exercised options to buy 17k shares at a strike price of around kr3.78, costing a total of kr63k. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. Leland currently holds less than 1% of total shares outstanding. This was the only transaction from an insider over the last 12 months.分析記事 • Apr 07Here's Why Phase Holographic Imaging PHI (NGM:PHI) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Reported Earnings • Mar 30Third quarter 2023 earnings released: kr0.22 loss per share (vs kr0.47 loss in 3Q 2022)Third quarter 2023 results: kr0.22 loss per share (improved from kr0.47 loss in 3Q 2022). Revenue: kr3.26m (up 19% from 3Q 2022). Net loss: kr4.41m (loss narrowed 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.お知らせ • Jan 18+ 1 more updatePhase Holographic Imaging PHI AB (publ) Announces Management ChangesThe Board of Directors of Phase Holographic Imaging (PHI) has appointed the company's CFO, Patrik Eschricht, as the new CEO. In addition, the former CEO and founder of PHI, Peter Egelberg, has been appointed executive chairman of the Board. The former chairman, Mats Lundwall, will remain on the Board as vice chairman.Reported Earnings • Dec 22Second quarter 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in 2Q 2022)Second quarter 2023 results: kr0.26 loss per share. Revenue: kr2.73m (up 50% from 2Q 2022). Net loss: kr5.30m (loss widened 36% from 2Q 2022).お知らせ • Dec 21Phase Holographic Imaging PHI AB (publ) to Report Q3, 2023 Results on Mar 30, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2023 results on Mar 30, 2023Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Mattias Lundin was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Oct 12Is Phase Holographic Imaging PHI (NGM:PHI) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Sep 30First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr2.04m (down 14% from 1Q 2022). Net loss: kr5.75m (loss widened 29% from 1Q 2022).お知らせ • Sep 30Phase Holographic Imaging PHI AB (publ) to Report First Half, 2023 Results on Dec 21, 2022Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2023 results on Dec 21, 2022お知らせ • Sep 29Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 31, 2022Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 31, 2022. Agenda: Annual General Meeting.Reported Earnings • Jun 30Full year 2022 earnings released: kr1.76 loss per share (vs kr1.63 loss in FY 2021)Full year 2022 results: kr1.76 loss per share (down from kr1.63 loss in FY 2021). Revenue: kr8.17m (up 125% from FY 2021). Net loss: kr25.4m (loss widened 8.0% from FY 2021). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.お知らせ • Jun 29Phase Holographic Imaging PHI AB (publ) to Report Q1, 2023 Results on Sep 29, 2022Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2023 results on Sep 29, 2022Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Mattias Lundin was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 20Phase Holographic Imaging Introduces Non-Invasive Fluorescence UnitsPhase Holographic Imaging (PHI) is currently preparing fluorescence units for its first users. The HoloMonitor add-on fluorescence unit enables medical research laboratories to analyze the all-important genetic activity of individual cells as they multiply in a cell incubator - without the detrimental effects associated with conventional fluorescence microscopy. Until January 20, 2022, researchers had no choice but to harm their valuable cells each time they were imaged. However, most of the fluorescence images during an experiment are taken to track cell movement, not to observe the much slower genetic changes. The combination of imaging techniques allows HoloMonitor to track cell movement using frequent but harmless holographic imaging rather than harmful fluorescence imaging. This unique ability leads to a dramatic reduction of the number of required fluorescence images, which allows HoloMonitor users to minimize or eliminate the undesired toxic effects when characterizing individual cells and their genetic activity. The result is more cost-effective and reliable research outcomes.Reported Earnings • Dec 30Second quarter 2022 earnings: Revenues in line with analyst expectationsSecond quarter 2022 results: Revenue: kr1.82m (up 120% from 2Q 2021). Net loss: kr3.90m (loss narrowed 18% from 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 2% per year.分析記事 • Oct 07Here's Why Phase Holographic Imaging PHI (NGM:PHI) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 30First quarter 2022 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: kr2.37m (up kr2.24m from 1Q 2021). Net loss: kr4.47m (loss narrowed 30% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat.Reported Earnings • Jun 27Full year 2021 earnings released: kr1.63 loss per share (vs kr1.83 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: kr3.64m (down 4.4% from FY 2020). Net loss: kr23.5m (loss narrowed 11% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 19Third quarter 2021 earnings released: kr0.38 loss per share (vs kr0.41 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: kr770.0k (down 56% from 3Q 2020). Net loss: kr5.53m (loss narrowed 5.6% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Feb 23New 90-day low: kr22.80The company is down 14% from its price of kr26.40 on 24 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.Is New 90 Day High Low • Jan 26New 90-day low: kr23.65The company is down 15% from its price of kr27.90 on 27 October 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.お知らせ • Dec 15Phase Holographic Imaging PHI AB (publ) to Report Q3, 2021 Results on Mar 16, 2021Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2021 results on Mar 16, 2021Is New 90 Day High Low • Dec 11New 90-day low: kr25.25The company is down 28% from its price of kr34.95 on 11 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.Is New 90 Day High Low • Nov 23New 90-day low: kr27.25The company is down 24% from its price of kr35.95 on 25 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.お知らせ • Nov 01Phase Holographic Imaging PHI AB (publ) to Report Q2, 2021 Results on Dec 14, 2020Phase Holographic Imaging PHI AB (publ) announced that they will report Q2, 2021 results on Dec 14, 2020Is New 90 Day High Low • Oct 19New 90-day low: kr28.65The company is down 14% from its price of kr33.20 on 20 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 11% over the same period.Is New 90 Day High Low • Oct 02New 90-day low: kr28.70The company is down 13% from its price of kr33.00 on 03 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period.Reported Earnings • Sep 29First quarter earnings releasedOver the last 12 months the company has reported total losses of kr25.6m, largely unchanged from the prior year. Total revenue was kr3.34m over the last 12 months, down 23% from the prior year.お知らせ • Aug 29Phase Holographic Imaging PHI AB (publ) to Report First Half, 2021 Results on Sep 28, 2020Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2021 results on Sep 28, 2020お知らせ • Jul 26Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2020 Final Results on Sep 01, 2020Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2020 final results on Sep 01, 2020株主還元PHISE Medical EquipmentSE 市場7D0%1.1%1.7%1Y31.8%-8.7%12.5%株主還元を見る業界別リターン: PHI過去 1 年間で-8.7 % の収益を上げたSwedish Medical Equipment業界を上回りました。リターン対市場: PHI過去 1 年間で12.5 % の収益を上げたSwedish市場を上回りました。価格変動Is PHI's price volatile compared to industry and market?PHI volatilityPHI Average Weekly Movementn/aMedical Equipment Industry Average Movement7.7%Market Average Movement6.1%10% most volatile stocks in SE Market13.0%10% least volatile stocks in SE Market3.4%安定した株価: PHI 、 Swedish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のPHIのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト199713Patrik Eschrichtphiab.comもっと見るPhase Holographic Imaging PHI AB (publ) 基礎のまとめPhase Holographic Imaging PHI の収益と売上を時価総額と比較するとどうか。PHI 基礎統計学時価総額SEK 169.21m収益（TTM）-SEK 22.54m売上高(TTM)SEK 10.69m15.8xP/Sレシオ-7.5xPER（株価収益率PHI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PHI 損益計算書（TTM）収益SEK 10.69m売上原価SEK 3.68m売上総利益SEK 7.01mその他の費用SEK 29.55m収益-SEK 22.54m直近の収益報告Jan 31, 2024次回決算日Jun 26, 2024一株当たり利益（EPS）-0.86グロス・マージン65.56%純利益率-210.82%有利子負債／自己資本比率167.0%PHI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/29 20:44終値2024/01/31 00:00収益2024/01/31年間収益2023/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Phase Holographic Imaging PHI AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 01Phase Holographic Imaging Announces Resignation of Mats Lundwall as Director, Effective December 30, 2025Phase Holographic Imaging announced that Mats Lundwall, at his own request, has resigned from his position on the company's Board of Directors, effective December 30, 2025.
お知らせ • Sep 26Phase Holographic Imaging PHI AB (publ) to Report First Half, 2026 Results on Dec 19, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2026 results on Dec 19, 2025
お知らせ • Aug 28Phase Holographic Imaging PHI AB (publ) to Report Q1, 2026 Results on Sep 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2026 results on Sep 26, 2025
お知らせ • Jun 26Phase Holographic Imaging Phi AB (Publ) Announces Executive and Board Appointments, Effective from 1 July 2025Phase Holographic Imaging PHI AB (publ) announced appointment of Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for company's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities. Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025.
お知らせ • May 28Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2025 Results on Jun 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2025 results on Jun 26, 2025
お知らせ • May 23Phase Holographic Imaging Phi AB (publ) Revises Revenue Guidance for Fiscal Year Ended on April 30, 2025Phase Holographic Imaging PHI AB (publ) revised revenue guidance for Fiscal Year ended on April 30, 2025. For the period, the company expects total sales to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.
お知らせ • Jan 01Phase Holographic Imaging Announces Resignation of Mats Lundwall as Director, Effective December 30, 2025Phase Holographic Imaging announced that Mats Lundwall, at his own request, has resigned from his position on the company's Board of Directors, effective December 30, 2025.
お知らせ • Sep 26Phase Holographic Imaging PHI AB (publ) to Report First Half, 2026 Results on Dec 19, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2026 results on Dec 19, 2025
お知らせ • Aug 28Phase Holographic Imaging PHI AB (publ) to Report Q1, 2026 Results on Sep 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2026 results on Sep 26, 2025
お知らせ • Jun 26Phase Holographic Imaging Phi AB (Publ) Announces Executive and Board Appointments, Effective from 1 July 2025Phase Holographic Imaging PHI AB (publ) announced appointment of Håkan Rosvall, currently the President of PHI's US operations, has been appointed the Chief Commercial Officer (CCO) for company's global operations. In his new role, Rosvall will oversee the Company's commercial strategy and drive global sales initiatives. Rosvall has been a part of PHI since 2010 and joined the PHI team when the Company had launched its first product - HoloMonitor M3 - and was then responsible for building up the distribution network worldwide. Since then, Rosvall has been in different roles, most recently president of PHI's subsidiary in the USA. Rosvall will start his new position in July 2025 and will relocate back to Sweden to assume his new responsibilities. Additionally, PHI is excited to announce the appointment of Casey Clark, PhD as the new President of PHI's subsidiary in the USA. Casey will be stationed at the Wake Forest Institute for Regenerative Medicine in Winston-Salem, NC, where he will lead the Company's US operations and clinical research. These organisational changes will take effect on 1 July 2025.
お知らせ • May 28Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2025 Results on Jun 26, 2025Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2025 results on Jun 26, 2025
お知らせ • May 23Phase Holographic Imaging Phi AB (publ) Revises Revenue Guidance for Fiscal Year Ended on April 30, 2025Phase Holographic Imaging PHI AB (publ) revised revenue guidance for Fiscal Year ended on April 30, 2025. For the period, the company expects total sales to amount to approximately EUR 1.5 million, compared to the estimate of EUR 2 million, communicated through a sales outlook in December 2024.
お知らせ • Mar 12Phase Holographic Imaging Announces Next Generation HoloMonitorPhase Holographic Imaging (PHI) announced that the next generation of PHI's live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internationally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine. The HoloMonitor CellSync marks the first in a series of models, with the long-term goal of delivering a clinical-grade product designed to set a new standard for automated quality control in cell and gene therapy manufacturing. The series is expected to include the latest developments in image processing and artificial intelligence. Manufactured by production partner in accordance with ISO 9001 standards, the HoloMonitor CellSync builds on the success of its predecessor, offering non-invasive, real-time imaging of live cells. It incorporates the latest advancements in PHI's core imaging technology, including an updated camera module and enhanced automated cell segmentation, which has been developed over the past two years.
お知らせ • Feb 11Phase Holographic Imaging Announces CEO ChangesRecent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company's clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead. Anders will step down immediately and assist with the transition. Ivan Jurkovic, PHI board member and Altium group CFO, will serve as the acting CEO of PHI during the recruitment process. In his current technology developer role, PHI's founding board member and former CEO, Peter Egelberg, will assist in product development and technical matters. Ivan Jurkovic (Board member, born 1984) is an experienced financial executive with experience in the pharmaceutical industry, beverage industry and IT industry. Mr. Jurkovic currently holds the position of Chief Financial Officer at Altium SA. As part of his role at Altium, Mr. Jurkovic is responsible for Altium's financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth.
お知らせ • Nov 20Phase Holographic Imaging PHI AB (publ) to Report First Half, 2025 Results on Dec 19, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2025 results on Dec 19, 2024
お知らせ • Nov 14Phase Holographic Imaging PHI AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 64.312816 million.Phase Holographic Imaging PHI AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 64.312816 million. Security Name: Shares Security Type: Common Stock Securities Offered: 35,729,342 Price\Range: SEK 1.8 Transaction Features: Rights Offering
お知らせ • Oct 17Phase Holographic Imaging Announces CEO Changes, Effective November 1, 2024The board of Phase Holographic Imaging (PHI) has appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson. Starting November 1, 2024, Anders Månsson will succeed Patrik Eschricht as CEO of PHI. Månsson brings over 25 years of experience in the international Health & Life Sciences field, having held senior-level positions in both large multinationals and smaller biotech companies. Most recently, he served as CEO of Oncoinvent ASA, and he has also held numerous leadership roles, including CEO, Chairman, and Board Member positions. He is currently a board member of EQL Pharma AB and a Partner and Board Member at Immetric AB. Månsson's previous roles also include CEO of LIDDS AB, the biopharmaceutical company RhoVac AB, and stem cell research-based company Amniotics AB. He studied for an Executive MBA at Business School Lausanne, Switzerland. As CEO of PHI, Anders will be responsible for driving the company's future development, with a particular focus on R&D, product development, and establishing PHI as a leader in non-invasive cell quality control technologies.
お知らせ • Jul 24Phase Holographic Imaging PHI AB (publ) to Report Q3, 2025 Results on Aug 19, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2025 results on Aug 19, 2024
お知らせ • Jul 22Phase Holographic Imaging PHI AB (publ) Announces Resignation of Leland Foster as Board MemberPhase Holographic Imaging PHI AB (publ) announced resignation of Leland Foster as board member. Mr. Foster has decided to resign from his position due to his age and his desire to retire from professional commitments effective from July 22, 2024. Leland Foster, elected board member in 2012, has been a pivotal figure on PHI's board, providing invaluable guidance and insight drawn from his extensive experience in the industry. His contributions have been instrumental in steering the company towards innovation and growth.
お知らせ • Jun 27Phase Holographic Imaging PHI AB (publ) to Report Q1, 2025 Results on Sep 16, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2025 results on Sep 16, 2024
お知らせ • Mar 27Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2024 Results on Jun 26, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2024 results on Jun 26, 2024
お知らせ • Mar 14Phase Holographic Imaging PHI AB (Publ) Appoints Ivan Jurkovic as Ordinary Board MemberPhase Holographic Imaging PHI AB (publ) held an extraordinary general meeting. The extraordinary general meeting resolved that the board of directors shall consist of six (6) ordinary board members, without deputy board members. For the period until the next annual general meeting, the general meeting resolved to elect Ivan Jurkovic as ordinary board member. Ivan Jurkovic, born in 1984, is an experienced financial business executive with experience from the pharmaceutical, beverage and IT industries. Jurkovic currently holds the position of Chief Financial Officer of Altium S.A. Within the scope of his assignment at Altium S.A., Jurkovic is responsible for the financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth.
お知らせ • Jan 31Phase Holographic Imaging PHI AB (publ) to Report Q3, 2024 Results on Mar 27, 2024Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2024 results on Mar 27, 2024
Reported Earnings • Dec 21Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr1.23m (down 55% from 2Q 2023). Net loss: kr5.38m (loss widened 1.3% from 2Q 2023).
分析記事 • Nov 07Phase Holographic Imaging PHI (NGM:PHI) Is Making Moderate Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Sep 21Phase Holographic Imaging PHI AB (publ) to Report First Half, 2024 Results on Dec 21, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2024 results on Dec 21, 2023
Reported Earnings • Sep 20First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr2.73m (up 34% from 1Q 2023). Net loss: kr4.30m (loss narrowed 25% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
お知らせ • Sep 17Phase Holographic Imaging PHI AB (publ) to Report Q1, 2024 Results on Sep 20, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2024 results on Sep 20, 2023
分析記事 • Jul 25Phase Holographic Imaging PHI (NGM:PHI) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Jul 04European Patent Office Intends to Grant Phase Holographic Imaging AB Patent on Synthetic AntibodiesPhase Holographic Imaging AB (PHI) announces that the European Patent Office (EPO) intends to grant a patent on synthetic antibodies. The patent application "EP329447 Molecularly Imprinted Polymers" was submitted by PHI together with Germany's federal institute for materials research (BAM). PHI's corresponding patents concerning synthetic antibodies in the US and Japan were granted in 2020 and 2022, respectively. In spring 2023, PHI established the subsidiary PHI MIPS AB to house the synthetic antibody patent family and facilitate its business potential for the GlycoImaging project's outcome.
お知らせ • Jun 27Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 12, 2023Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 12, 2023.
Reported Earnings • Jun 27Full year 2023 earnings released: kr1.13 loss per share (vs kr1.76 loss in FY 2022)Full year 2023 results: kr1.13 loss per share (improved from kr1.76 loss in FY 2022). Revenue: kr9.90m (up 21% from FY 2022). Net loss: kr23.2m (loss narrowed 8.7% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings.
お知らせ • May 25Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2023 Results on Jun 23, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2023 results on Jun 23, 2023
お知らせ • May 10Phase Holographic Imaging Phi AB (Publ) Elects Goran Dubravcic Elected as A New Member of the BoardPhase Holographic Imaging Phi AB (Publ) announced that Goran Dubravcic elected as a new member of the Board. The newly elected board member Goran Dubravcic is the CEO of Altium SA, which currently owns 11.8% of the shares in the Company.
Recent Insider Transactions Derivative • May 08Director exercised options to buy kr105k worth of stock.On the 2nd of May, Leland Foster exercised options to buy 17k shares at a strike price of around kr3.78, costing a total of kr63k. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. Leland currently holds less than 1% of total shares outstanding. This was the only transaction from an insider over the last 12 months.
分析記事 • Apr 07Here's Why Phase Holographic Imaging PHI (NGM:PHI) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Reported Earnings • Mar 30Third quarter 2023 earnings released: kr0.22 loss per share (vs kr0.47 loss in 3Q 2022)Third quarter 2023 results: kr0.22 loss per share (improved from kr0.47 loss in 3Q 2022). Revenue: kr3.26m (up 19% from 3Q 2022). Net loss: kr4.41m (loss narrowed 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
お知らせ • Jan 18+ 1 more updatePhase Holographic Imaging PHI AB (publ) Announces Management ChangesThe Board of Directors of Phase Holographic Imaging (PHI) has appointed the company's CFO, Patrik Eschricht, as the new CEO. In addition, the former CEO and founder of PHI, Peter Egelberg, has been appointed executive chairman of the Board. The former chairman, Mats Lundwall, will remain on the Board as vice chairman.
Reported Earnings • Dec 22Second quarter 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in 2Q 2022)Second quarter 2023 results: kr0.26 loss per share. Revenue: kr2.73m (up 50% from 2Q 2022). Net loss: kr5.30m (loss widened 36% from 2Q 2022).
お知らせ • Dec 21Phase Holographic Imaging PHI AB (publ) to Report Q3, 2023 Results on Mar 30, 2023Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2023 results on Mar 30, 2023
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Mattias Lundin was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 12Is Phase Holographic Imaging PHI (NGM:PHI) Using Debt In A Risky Way?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Sep 30First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr2.04m (down 14% from 1Q 2022). Net loss: kr5.75m (loss widened 29% from 1Q 2022).
お知らせ • Sep 30Phase Holographic Imaging PHI AB (publ) to Report First Half, 2023 Results on Dec 21, 2022Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2023 results on Dec 21, 2022
お知らせ • Sep 29Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 31, 2022Phase Holographic Imaging PHI AB (publ), Annual General Meeting, Oct 31, 2022. Agenda: Annual General Meeting.
Reported Earnings • Jun 30Full year 2022 earnings released: kr1.76 loss per share (vs kr1.63 loss in FY 2021)Full year 2022 results: kr1.76 loss per share (down from kr1.63 loss in FY 2021). Revenue: kr8.17m (up 125% from FY 2021). Net loss: kr25.4m (loss widened 8.0% from FY 2021). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
お知らせ • Jun 29Phase Holographic Imaging PHI AB (publ) to Report Q1, 2023 Results on Sep 29, 2022Phase Holographic Imaging PHI AB (publ) announced that they will report Q1, 2023 results on Sep 29, 2022
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Mattias Lundin was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 20Phase Holographic Imaging Introduces Non-Invasive Fluorescence UnitsPhase Holographic Imaging (PHI) is currently preparing fluorescence units for its first users. The HoloMonitor add-on fluorescence unit enables medical research laboratories to analyze the all-important genetic activity of individual cells as they multiply in a cell incubator - without the detrimental effects associated with conventional fluorescence microscopy. Until January 20, 2022, researchers had no choice but to harm their valuable cells each time they were imaged. However, most of the fluorescence images during an experiment are taken to track cell movement, not to observe the much slower genetic changes. The combination of imaging techniques allows HoloMonitor to track cell movement using frequent but harmless holographic imaging rather than harmful fluorescence imaging. This unique ability leads to a dramatic reduction of the number of required fluorescence images, which allows HoloMonitor users to minimize or eliminate the undesired toxic effects when characterizing individual cells and their genetic activity. The result is more cost-effective and reliable research outcomes.
Reported Earnings • Dec 30Second quarter 2022 earnings: Revenues in line with analyst expectationsSecond quarter 2022 results: Revenue: kr1.82m (up 120% from 2Q 2021). Net loss: kr3.90m (loss narrowed 18% from 2Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has fallen by 2% per year.
分析記事 • Oct 07Here's Why Phase Holographic Imaging PHI (NGM:PHI) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 30First quarter 2022 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: kr2.37m (up kr2.24m from 1Q 2021). Net loss: kr4.47m (loss narrowed 30% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat.
Reported Earnings • Jun 27Full year 2021 earnings released: kr1.63 loss per share (vs kr1.83 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: kr3.64m (down 4.4% from FY 2020). Net loss: kr23.5m (loss narrowed 11% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 19Third quarter 2021 earnings released: kr0.38 loss per share (vs kr0.41 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: kr770.0k (down 56% from 3Q 2020). Net loss: kr5.53m (loss narrowed 5.6% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Feb 23New 90-day low: kr22.80The company is down 14% from its price of kr26.40 on 24 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.
Is New 90 Day High Low • Jan 26New 90-day low: kr23.65The company is down 15% from its price of kr27.90 on 27 October 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 16% over the same period.
お知らせ • Dec 15Phase Holographic Imaging PHI AB (publ) to Report Q3, 2021 Results on Mar 16, 2021Phase Holographic Imaging PHI AB (publ) announced that they will report Q3, 2021 results on Mar 16, 2021
Is New 90 Day High Low • Dec 11New 90-day low: kr25.25The company is down 28% from its price of kr34.95 on 11 September 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Nov 23New 90-day low: kr27.25The company is down 24% from its price of kr35.95 on 25 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.
お知らせ • Nov 01Phase Holographic Imaging PHI AB (publ) to Report Q2, 2021 Results on Dec 14, 2020Phase Holographic Imaging PHI AB (publ) announced that they will report Q2, 2021 results on Dec 14, 2020
Is New 90 Day High Low • Oct 19New 90-day low: kr28.65The company is down 14% from its price of kr33.20 on 20 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 11% over the same period.
Is New 90 Day High Low • Oct 02New 90-day low: kr28.70The company is down 13% from its price of kr33.00 on 03 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 18% over the same period.
Reported Earnings • Sep 29First quarter earnings releasedOver the last 12 months the company has reported total losses of kr25.6m, largely unchanged from the prior year. Total revenue was kr3.34m over the last 12 months, down 23% from the prior year.
お知らせ • Aug 29Phase Holographic Imaging PHI AB (publ) to Report First Half, 2021 Results on Sep 28, 2020Phase Holographic Imaging PHI AB (publ) announced that they will report first half, 2021 results on Sep 28, 2020
お知らせ • Jul 26Phase Holographic Imaging PHI AB (publ) to Report Fiscal Year 2020 Final Results on Sep 01, 2020Phase Holographic Imaging PHI AB (publ) announced that they will report fiscal year 2020 final results on Sep 01, 2020
